Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024)
Zentalis Pharmaceuticals' quarterly Income from Non-Controlling Interests came in at -$28000.0 in Q1 2024, up 34.88% year-on-year from -$20758.6 in Q2 2023, and down 27.27% quarter-over-quarter from -$22000.0 in Q4 2023.
Zentalis Pharmaceuticals has reported Income from Non-Controlling Interests for 6 years, with the latest figure at -$28000.0 in Q1 2024.
- For the quarter ending Q1 2024, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0; the trailing twelve-month figure through Dec 2024 stood at -$28000.0 (up 75.44% YoY), and the FY2024 full-year result was -$28000.0, up 75.44% from the prior year.
- Income from Non-Controlling Interests for Q1 2024 stood at -$28000.0, down from -$22000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$12000.0 in Q3 2023, with the low at -$6.3 million in Q3 2021.
- Average Income from Non-Controlling Interests over 5 years is -$501411.8, with a median of -$53000.0 recorded in 2020.
- Year-over-year, Income from Non-Controlling Interests plunged 5628.18% in 2021 and jumped 98.43% in 2022.
- Tracing ZNTL's Income from Non-Controlling Interests over 5 years: stood at -$53000.0 in 2020, then soared by 32.08% to -$36000.0 in 2021, then soared by 63.89% to -$13000.0 in 2022, then tumbled by 69.23% to -$22000.0 in 2023, then dropped by 27.27% to -$28000.0 in 2024.
- The last three Income from Non-Controlling Interests figures came in at -$28000.0 (Q1 2024), -$22000.0 (Q4 2023), and -$12000.0 (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | -37,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -99,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -160,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | -6.30 Mn |
| Jun 30, 2021 | -488,000.00 |
| Mar 31, 2021 | -543,000.00 |
| Dec 31, 2020 | -53,000.00 |
| Sep 30, 2020 | -110,000.00 |
| Jun 30, 2020 | -435,000.00 |
| Mar 31, 2020 | -109,000.00 |
| Dec 31, 2019 | -40,000.00 |
| Sep 30, 2019 | -228,000.00 |
| Jun 30, 2019 | -127,000.00 |
| Mar 31, 2019 | -320,000.00 |